Eversept Partners LLC bought a new stake in ABIOMED, Inc. (NASDAQ:ABMD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,594 shares of the medical equipment provider’s stock, valued at approximately $1,611,000. ABIOMED makes up 1.3% of Eversept Partners LLC’s portfolio, making the stock its 21st largest holding.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Crow Point Partners LLC bought a new stake in ABIOMED in the 4th quarter valued at approximately $120,000. Cerebellum GP LLC bought a new stake in ABIOMED in the 4th quarter valued at approximately $127,000. Advisor Partners LLC bought a new stake in shares of ABIOMED during the 4th quarter worth approximately $209,000. SeaCrest Wealth Management LLC bought a new stake in shares of ABIOMED during the 4th quarter worth approximately $183,000. Finally, Flagship Harbor Advisors LLC bought a new stake in shares of ABIOMED during the 4th quarter worth approximately $242,000. Hedge funds and other institutional investors own 86.99% of the company’s stock.
Shares of ABIOMED, Inc. (NASDAQ:ABMD) opened at $268.25 on Thursday. ABIOMED, Inc. has a 12 month low of $114.28 and a 12 month high of $274.00. The stock has a market capitalization of $11,976.27, a P/E ratio of 135.48, a PEG ratio of 3.59 and a beta of 0.36.
A number of equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price objective on the stock in a research note on Tuesday, November 7th. BTIG Research reiterated a “hold” rating on shares of ABIOMED in a research note on Sunday, February 4th. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Piper Jaffray Companies reiterated a “positive” rating and set a $300.00 price objective (up previously from $220.00) on shares of ABIOMED in a research note on Thursday, February 1st. Finally, Leerink Swann upped their price objective on ABIOMED from $200.00 to $265.00 and gave the stock an “outperform” rating in a research note on Friday, January 19th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $288.86.
ILLEGAL ACTIVITY NOTICE: “Eversept Partners LLC Buys New Position in ABIOMED, Inc. (ABMD)” was first reported by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://weekherald.com/2018/02/22/eversept-partners-llc-buys-new-position-in-abiomed-inc-abmd.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.